Article Text

A8.39 Regulatory role for CD72 Expression on B cells in SLE
  1. Zahava Vadasz,
  2. Elias Toubi
  1. Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel


Background B regulatory cells and their regulatory products/markers, such us semaphorin3A (sema3A) and its receptor NP-1, FcγIIB, IL-10, and others, act at the very base of self-tolerance maintenance and prevention of autoimmune disease development.

Objectives The aim of the present study was to assess the involvement of CD72, a regulatory receptor on B cells, in systemic lupus erythematosus (SLE). In addition, the potential of soluble sema3A in enhancing the expression of CD72 on B cells of SLE patients was investigated.

Results CD72 expression on B cells of SLE patients was significantly lower than that of normal controls. This lower expression of CD72 in SLE patients correlated inversely with SLE disease activity and was associated with lupus nephritis, the presence of anti-dsDNA antibodies and with low levels of complement. Co-culture of purified B cells from healthy controls with soluble sema3A resulted in significant enhancement of CD72. Similar enhancement of CD72 on B cells from SLE patients, though significant, was still lower than in normal individuals.

Conclusions The lower expression of CD72 on B cells from SLE patients correlates with SLE disease activity, lupus nephritis, the presence of anti dsDNA antibodies, and low levels of complement. The improvement of CD72 expression following the addition of soluble semaphorin3A suggests that CD72 may be useful as a biomarker to be followed during the treatment of SLE.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.